Chinese Drug Regulator Accepts Aosaikang Pharma Unit's Marketing Application for Isavuconazole Sulfate Capsules; Shares Down 4%

MT NewswiresFeb 11 14:10

Express News | Beijing Aosaikang Pharmaceutical: The subsidiary will present the research results of the Innovative Drug ASKB589 for first-line treatment of advanced gastric cancer at the 2025 ASCO GI.

BreakingsJan 24 08:11

Beijing Aosaikang Pharmaceutical (002755.SZ): Expected profit of 0.15 billion yuan to -0.195 billion yuan for the year 2024, turning losses into profits compared to the same period last year.

Gelonghui, January 22丨Beijing Aosaikang Pharmaceutical (002755.SZ) announced its earnings forecast for the 2024 fiscal year, with net income attributable to shareholders of the listed company expected to be between 0.15 billion yuan and 0.195 billion yuan, turning a profit compared to the previous year; net income excluding non-recurring gains and losses is expected to be between 0.116 billion yuan and 0.15 billion yuan; and basic EPS is expected to be between 0.17 yuan/share and 0.22 yuan/share. The company’s sales of anti-infection and chronic disease products are growing rapidly, and its revenue has achieved year-on-year growth with enhanced profitability. The company continues to analyze, evaluate, and optimize its R&D projects, focusing on promoting key advantageous products.

Gelonghui FinanceJan 22 17:13

Aosaikang Pharma's Unit Gets Registration Certificate for Trifluridine Tipiperimidine Tablets

MT NewswiresJan 21 18:43

Beijing Aosaikang Pharmaceutical (002755.SZ): Subsidiary Qufu Nucleoside and Pyrimethamine Tablets obtained Pharmaceutical registration certificate.

Gelonghui, on January 20, reported that Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its wholly-owned subsidiary Jiangsu Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as "the subsidiary") recently received the Drug Registration Certificate issued by the National Medical Products Administration for the compound drug Capecitabine and Methylprednisolone Tablets. Capecitabine and Methylprednisolone Tablets are an oral compound nucleoside chemotherapeutic drug composed of Capecitabine and Methylprednisolone in a molar ratio of 1:0.5, suitable for patients who have previously undergone chemotherapy based on Fluorouracil, Oxaliplatin, and Irinotecan, as well as those who have previously received or are unsuitable for anti-vascular endothelial growth factor (VEGF) treatment, and anti-surface.

Gelonghui FinanceJan 20 19:41

Express News | Beijing Aosaikang Pharmaceutical: The subsidiary's capecitabine and tecelebrine tablets have obtained the Pharmaceutical registration certificate.

BreakingsJan 20 18:41